Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Long-Term Debt Repayments (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Long-Term Debt Repayments for 7 consecutive years, with $462000.0 as the latest value for Q1 2025.

  • Quarterly Long-Term Debt Repayments fell 98.74% to $462000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $462000.0 through Dec 2025, down 98.75% year-over-year, with the annual reading at $462000.0 for FY2025, 98.75% down from the prior year.
  • Long-Term Debt Repayments for Q1 2025 was $462000.0 at Akebia Therapeutics, up from -$1000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $36.7 million in Q1 2024, with the low at -$1000.0 in Q4 2024.
  • Average Long-Term Debt Repayments over 4 years is $12.8 million, with a median of $8.0 million recorded in 2023.
  • Peak annual rise in Long-Term Debt Repayments hit 129.54% in 2024, while the deepest fall reached 100.01% in 2024.
  • Over 4 years, Long-Term Debt Repayments stood at $33.0 million in 2022, then tumbled by 75.76% to $8.0 million in 2023, then plummeted by 100.01% to -$1000.0 in 2024, then surged by 46300.0% to $462000.0 in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods came in at $462000.0, -$1000.0, and $374000.0 for Q1 2025, Q4 2024, and Q2 2024 respectively.